Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells (2010)
- Authors:
- USP affiliated authors: HIRATA, MARIO HIROYUKI - FCF ; DOREA, EGIDIO LIMA - HU ; CURI, RUI - ICB ; HIRATA, ROSARIO DOMINGUEZ CRESPO - FCF
- Unidades: FCF; HU; ICB
- DOI: 10.2217/pgs.10.93
- Subjects: EXPRESSÃO GÊNICA; COLESTEROL; LIPOPROTEÍNAS LDL
- Language: Inglês
- Imprenta:
- Source:
- Título: Pharmacogenomics
- ISSN: 1462-2416
- Volume/Número/Paginação/Ano: v. 11, n. 9, p. 1235-1246, 2010
- Status:
- Artigo possui versão em acesso aberto em repositório (Green Open Access)
- Versão do Documento:
- Versão submetida (Pré-print)
- Acessar versão aberta:
-
ABNT
GENVIGIR, Fabiana Dalla Vecchia et al. Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells. Pharmacogenomics, v. 11, n. 9, p. 1235-1246, 2010Tradução . . Disponível em: https://doi.org/10.2217/pgs.10.93. Acesso em: 15 abr. 2026. -
APA
Genvigir, F. D. V., Rodrigues, A. C., Cerda, A., Arazi, S. S., Willrich, M. A. V., Oliveira, R., et al. (2010). Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells. Pharmacogenomics, 11( 9), 1235-1246. doi:10.2217/pgs.10.93 -
NLM
Genvigir FDV, Rodrigues AC, Cerda A, Arazi SS, Willrich MAV, Oliveira R, Hirata MH, Dórea EL, Bernik MMS, Curi R, Hirata RDC. Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells [Internet]. Pharmacogenomics. 2010 ; 11( 9): 1235-1246.[citado 2026 abr. 15 ] Available from: https://doi.org/10.2217/pgs.10.93 -
Vancouver
Genvigir FDV, Rodrigues AC, Cerda A, Arazi SS, Willrich MAV, Oliveira R, Hirata MH, Dórea EL, Bernik MMS, Curi R, Hirata RDC. Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells [Internet]. Pharmacogenomics. 2010 ; 11( 9): 1235-1246.[citado 2026 abr. 15 ] Available from: https://doi.org/10.2217/pgs.10.93 - Leptin receptor gene polymorphisms are associated with adiposity and metabolic alterations in Brazilian individuals
- Relationships among CYP3A4 and CYP3A5 haplotypes, mRNA expression, CYP3A activity and atorvastatin response in hypercholesterolemic individuals
- Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression
- The contribution of genetic polymorphisms in 60 candidate genes to variability in atorvastatin response
- CYP3A5*3A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia
- Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients
- Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response
- Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression
- Differentiation of african components of ancestry to stratify groups in a case-control study of a brazilian urban population
- Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
